Literature DB >> 10610018

Elevated serum triglycerides with clozapine resolved with risperidone in four patients.

P Ghaeli1, R L Dufresne.   

Abstract

Serum triglyceride levels of four patients with psychotic disorders were decreased after switching therapy from clozapine to risperidone. In two patients clozapine was reinstated after risperidone was discontinued; serum triglyceride levels increased. This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients. Other reports show increases with the atypical antipsychotics, olanzapine and quetiapine. We believe serum triglyceride levels should be monitored in patients who have other cardiac risk factors and are receiving clozapine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10610018     DOI: 10.1592/phco.19.13.1099.31586

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

Review 1.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

2.  A crossover study on lipid and weight changes associated with olanzapine and risperidone.

Authors:  Kuan-Pin Su; Po-Lun Wu; Carmine M Pariante
Journal:  Psychopharmacology (Berl)       Date:  2005-10-21       Impact factor: 4.530

3.  Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report.

Authors:  Saddichha Sahoo; Biswaranjan Mishra; Sayeed Akhtar
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

Review 4.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver.

Authors:  Johan Fernø; Audun O Vik-Mo; Goran Jassim; Bjarte Håvik; Kjetil Berge; Silje Skrede; Oddrun A Gudbrandsen; Jo Waage; Niclas Lunder; Sverre Mørk; Rolf K Berge; Hugo A Jørgensen; Vidar M Steen
Journal:  Psychopharmacology (Berl)       Date:  2008-10-30       Impact factor: 4.530

6.  Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths.

Authors:  Gary S. Kabinoff; Patrick A. Toalson; Kristine Masur Healey; Hillary C. McGuire; Donald P. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

Review 7.  Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.

Authors:  Kristina Melkersson; Marja-Liisa Dahl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  A Focused Review of the Metabolic Side-Effects of Clozapine.

Authors:  Jessica W Y Yuen; David D Kim; Ric M Procyshyn; William J Panenka; William G Honer; Alasdair M Barr
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

9.  Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides.

Authors:  Yanmei Li; Ruibing Su; Shuqin Xu; Qingjun Huang; Haiyun Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-27       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.